Seoane Reula E, Bellon J M, Gurbindo D, Muñoz-Fernandez M A
Division of Molecular Immunobiology, Laboratorio de Inmunobiología, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, 28007 Madrid, Spain.
Br J Dermatol. 2005 Aug;153(2):382-9. doi: 10.1111/j.1365-2133.2005.06758.x.
Human immunodeficiency virus (HIV) infection causes a severe cellular immunodeficiency, which results in a greater susceptibility to infectious, inflammatory and malignant conditions. Among these, pathologies of the skin seem to be those most frequently observed in HIV+ patients. However, there are few reports on how antiretroviral therapy affects skin disorders in HIV-infected children.
To study the incidence and prevalence of skin disorders in a cohort of HIV-infected children, in relation to the antiviral therapy [nontreated, monotherapy, combined therapy and highly active antiretroviral therapy (HAART)] received, and their impact on immunological and virological markers. The treatments were those available in different calendar periods in the history of antiviral treatment.
A retrospective, observational study in a cohort of 210 HIV-infected children was carried out. These children were followed up every 3 months throughout 22 years. The viral load (HIV RNA copies mL(-1)) was quantified using reverse transcriptase-polymerase chain reaction and the viral phenotype of HIV-1 isolates was determined by in vitro culture. T-lymphocyte subsets in peripheral blood were quantified by flow cytometry.
Mucocutaneous manifestations were diagnosed in 17% of the untreated infected children. Of the treated children in different treatment periods, 22% in the monotherapy period, 25% in the combined therapy period but only 10% on HAART had some type of mucocutaneous manifestation, concordant with a higher number of CD4+ T cells, a lower viral load and less cytopathic virus in the last group. Mucocutaneous manifestations of infectious aetiology were most frequently observed; they were detected in 13% of the children during the first calendar period (untreated children), 16% during the second and third periods (monotherapy and combined therapy) and only 5% in the last period (HAART). Interestingly, syncytium-inducing virus was present in 69% of all children with mucocutaneous manifestations of infectious aetiology.
Only in the last calendar period (HAART) was a significant decrease observed in the prevalence of mucocutaneous manifestations with HIV infection associated with an increase in CD4+ T cells. In addition, we found a strong association between children who had mucocutaneous manifestations with an infectious aetiology and a more cytopathic (X4/SI) viral phenotype.
人类免疫缺陷病毒(HIV)感染会导致严重的细胞免疫缺陷,从而使人更易感染传染性疾病、炎症性疾病和恶性疾病。其中,皮肤病变似乎是HIV阳性患者中最常见的疾病。然而,关于抗逆转录病毒疗法如何影响HIV感染儿童的皮肤疾病,相关报道较少。
研究一组HIV感染儿童皮肤疾病的发病率和患病率,以及与所接受的抗病毒治疗[未治疗、单一疗法、联合疗法和高效抗逆转录病毒疗法(HAART)]的关系,及其对免疫和病毒学指标的影响。这些治疗方法是抗病毒治疗历史上不同时期可用的方法。
对一组210名HIV感染儿童进行了一项回顾性观察研究。在22年期间,每3个月对这些儿童进行一次随访。使用逆转录聚合酶链反应定量病毒载量(HIV RNA拷贝数/mL),并通过体外培养确定HIV-1分离株的病毒表型。通过流式细胞术对外周血中的T淋巴细胞亚群进行定量。
在未接受治疗的感染儿童中,17%被诊断出有皮肤黏膜表现。在不同治疗时期接受治疗的儿童中,单一疗法时期有22%,联合疗法时期有25%,但接受HAART治疗的儿童中只有10%有某种类型的皮肤黏膜表现,这与最后一组中较高数量的CD4+T细胞、较低的病毒载量和较少的细胞病变病毒一致。感染性病因引起的皮肤黏膜表现最为常见;在第一个日历期(未治疗儿童),13%的儿童出现这种表现,在第二个和第三个时期(单一疗法和联合疗法)为16%,在最后一个时期(HAART)仅为5%。有趣的是,在所有有感染性病因的皮肤黏膜表现的儿童中,69%存在诱导融合病毒。
仅在最后一个日历期(HAART),观察到HIV感染相关的皮肤黏膜表现患病率显著下降,同时CD4+T细胞增加。此外,我们发现有感染性病因的皮肤黏膜表现的儿童与细胞病变程度更高(X4/SI)的病毒表型之间存在密切关联。